NCT07326709ClinicalTrials.gov
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
A Randomized, Placebo-controlled, Double-blind Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
باختصار
The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518…
المرحلة 3مطلوب 770 مشاركاً117 موقعاً27 دولة
الفئات
مسجَّلة في سجل واحد
- ClinicalTrials.govNCT07326709فتح هذا السجل في ClinicalTrials.govتمت المزامنة قبل شهرين
يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.
تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.
هل أنت مهتم بهذه الدراسة؟
تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-01-08; recorded start 2026-03-24
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 1147 other studies in this databaseCounted from the lead sponsor named in the record (Novartis Pharmaceuticals)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 41 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study, international in scope: 770 participants (target), run at 117 sites, across 27 countries.
How this score is built
- Enrolment28/40
770 participants (target)
- Site count19/25
41 sites
- Country count12/15
9 countries
- Planned duration9/10
Planned over about 50 months
- Sponsor scale10/10
Novartis Pharmaceuticals has led 1,104 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
ملخص
The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518 from PTC Therapeutics), HTT227 is Novartis code under Novartis sponsorship.
الحالات
- Huntington Disease
الأهلية
| الجنس | الجميع |
|---|---|
| الأعمار | 21 Years – 70 Years |
| المتطوعون الأصحّاء | لا |
الأهلية كما كُتبت في السجل
الأهلية في عبارات بسيطة
لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.
تصميم الدراسة
| نوع الدراسة | تدخّلية |
|---|---|
| المرحلة | المرحلة 3 |
| التخصيص | معشّاة |
| نموذج التدخّل | PARALLEL |
| الغرض الأساسي | TREATMENT |
| التعمية | QUADRUPLE (4) |
| التجنيد | مطلوب 770 مشاركاً |
الجهة الراعية والمتعاونون
- Novartis Pharmaceuticals الجهة الراعية
الأذرع والتدخلات
- VotoplamEXPERIMENTAL
Votoplam (blinded) taken orally, randomized in a 3:2 ratio (Votoplam: Placebo)
- PlaceboPLACEBO_COMPARATOR
Placebo (blinded) taken orally, randomized in a 3:2 ratio (Votoplam: Placebo)
التدخلات
- دواء Placebo
Placebo
- دواء Votoplam (blinded)
Votoplam (blinded) active treatment
مقاييس النتائج
مقياس النتيجة الأولي
Change from Baseline in cUHDRS score
The Composite Unified Huntingtons Disease Ratings Scale (cUHDRS) is an improved composite measure to assess multi-domain clinical progression in HD. The cUHDRS is a combined weighted score of measures of motor function (TMS), cognition (SDMT and SWRT) and overall functional capacity (TFC): cUHDRS = \[(TFC-10.4)/1.9 - (TMS-29.7)/14.9 + (SDMT-28.4)/11.3 + (SWRT - 66.1)/20.1\] + 10. In conjunction with one another, these measures provide a comprehensive, sensitive and specific tool for monitoring disease progression, with lower scores indicating more severe disease. cUHDRS score range from -8 to 25.
الإطار الزمني Baseline, Month 36
مقياس النتيجة الثانوي
Change from Baseline in UHDRS-TFC
The UHDRS-Total Functional Capacity (TFC) focuses on the Investigator's assessment of the participant's capacity to perform a range of activities including occupation, finances, self-care, domestic chores and activities of daily living. The responses are derived from interview with the participant and/or companion, if applicable. Scores range from 0 to 13, with higher scores representing better functioning.
الإطار الزمني Baseline, Month 36
مقياس النتيجة الثانوي
Change from Baseline in UHDRS-IS
The UHDRS-Independence Scale (IS) measures a patient's overall level of functional independence in activities of daily living. It provides a single score ranging from 10 (total dependence/bedbound) to 100 (no special care needed) in intervals of 10, with higher scores indicating better functioning. Scores can also be assigned in increments of 5 for intermediate levels of function.
الإطار الزمني Baseline, Month 36
مقياس النتيجة الثانوي
The time to decline in TFC score by at least one or IS score by at least 10
The UHDRS-Total Functional Capacity (TFC) focuses on the Investigator's assessment of the participant's capacity to perform a range of activities including occupation, finances, self-care, domestic chores and activities of daily living. The responses are derived from interview with the participant and/or companion, if applicable. Scores range from 0 to 13, with higher scores representing better functioning. The UHDRS-Independence Scale (IS) measures a patient's overall level of functional independence in activities of daily living. It provides a single score ranging from 10 (total dependence/bedbound) to 100 (no special care needed) in intervals of 10, with higher scores indicating better functioning. Scores can also be assigned in increments of 5 for intermediate levels of function.
الإطار الزمني Baseline to end of treatment up to 36 months
مقياس النتيجة الثانوي
Change from Baseline in UHDRS-TMS
The UHDRS-Total Motor Score (TMS) is the cumulative sum of the individual motor ratings obtained during the administration of the motor assessment portion of the UHDRS. It includes items related to eye movements, speech, limb movements (including hand taps and pronation-supination), dystonia, chorea, and gait/balance. Scores range from 0 to 124, with higher scores indicating greater motor impairment.
الإطار الزمني Baseline, Month 36
مقياس النتيجة الثانوي
Change from Baseline in SDMT
The Symbol Digit Modality Test (SDMT) is used to assess attention, working memory, psychomotor speed and visual perceptual processing. Participants are presented with a translation key of specific numbers paired with unique abstract symbols. Below the translation key is an array of symbols paired with empty spaces, the participant's task is to match the number for each symbol as quickly as possible in a given time frame. Scores are based on number of correctly paired items and range from 0 to 110, with higher scores representing better performance.
الإطار الزمني Baseline, Month 36
مقياس النتيجة الثانوي
Change from Baseline in SWRT
The Stroop Word Reading Test (SWRT) is a measure of processing and psychomotor speed. Participants are presented with a list or words (color names) printed in black ink and asked to read aloud as many words as possible within a set timeframe. Scores are based on the number of words read correctly and range from 0 to 60, with higher scores representing better performance.
الإطار الزمني Baseline, Month 36
مقياس النتيجة الثانوي
Percent change from Baseline in blood mHTT protein
The mutant huntington protein (mHTT) which is detectable both in blood and cerebrospinal fluid (CSF), represents a reliable biomarker for HD due to its direct involvement in disease pathology. Blood mHTT is a direct product of the pathogenic HTT gene mutation and represents a proximal marker of Huntington's disease (HD) biology.
الإطار الزمني Baseline to steady state and up to 36 months in blood mHTT protein
مقياس النتيجة الثانوي
Change from Baseline in serum NfL
Serum Neurofilament light chain NfL is a component of the neuronal cytoskeleton, released into CSF and blood after neuro-axonal damage, serving as a marker of neurodegeneration and disease progression in HD.
الإطار الزمني Baseline, Month 36
مقياس النتيجة الثانوي
Incidence and severity of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and TEAEs leading to participant withdrawal
Number of participants with AEs and SAEs, including notable findings on physical examination, changes in vital signs, laboratory parameters, ECG, etc.
الإطار الزمني Baseline to up to 36 months
التواريخ
| تاريخ البدء | 24 مارس 2026 (فعلي) |
|---|---|
| الإتمام الأولي | 2 أبريل 2030 (تقديري) |
| الإتمام | 30 أبريل 2030 (تقديري) |
| أول نشر | 8 يناير 2026 (فعلي) |
| آخر تحديث | 22 سبتمبر 2026 |
| النتائج منشورة | غير مذكور في سجل السجل |
| آخر تأكيد للحالة | سبتمبر 2026 |
فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.
المواقع
117 موقعاً قيد التجنيد
Argentina
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Novartis Investigative Site | Buenos Aires | قيد التجنيد | |
| Instituto Argentino de Investigación Neurológica (IADIN) | CABA | Buenos Aires | قيد التجنيد |
| Centro de Investigaciones Metabólicas (CINME) | CABA | Buenos Aires | قيد التجنيد |
| Novartis Investigative Site | Ciudad de | Buenos Aires | قيد التجنيد |
Australia
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Novartis Investigative Site | Caulfield South | Victoria | قيد التجنيد |
| Novartis Investigative Site | Westmead | New South Wales | قيد التجنيد |
Belgium
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Novartis Investigative Site | Leuven | Vlaams Brabant | قيد التجنيد |
Bulgaria
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Novartis Investigative Site | Sofia | قيد التجنيد | |
| Novartis Investigative Site | Sofia | قيد التجنيد |
Canada
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| CUSM Montreal Neurological Institute | Montreal | Quebec | قيد التجنيد |
| Centre de recherche du CHUM | Montreal | Quebec | قيد التجنيد |
| North York General Hospital | North York | Ontario | قيد التجنيد |
China
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Novartis Investigative Site | Beijing | قيد التجنيد | |
| Novartis Investigative Site | Beijing | قيد التجنيد | |
| The Second Xiangya Hospital of Central South University | Changsha | Hunan | قيد التجنيد |
| West China Hospital of Sichuan Uni | Chengdu | Sichuan | قيد التجنيد |
| Novartis Investigative Site | Fuzhou | Fujian | قيد التجنيد |
| Novartis Investigative Site | Guangzhou | Guangdong | قيد التجنيد |
| Novartis Investigative Site | Guangzhou | Guangdong | قيد التجنيد |
| The Second Affiliated Hosp Of Zhejiang Univ School Of Medicine | Hangzhou | Zhejiang | قيد التجنيد |
| Novartis Investigative Site | Shanghai | قيد التجنيد | |
| Tongji Hos Affiliated Tongji Medical College of Huazhong | Wuhan | Hubei | قيد التجنيد |
Colombia
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Novartis Investigative Site | Medellín | قيد التجنيد |
Czechia
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Novartis Investigative Site | Brno | قيد التجنيد | |
| Novartis Investigative Site | Prague | قيد التجنيد |
Denmark
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Novartis Investigative Site | Copenhagen | قيد التجنيد |
France
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Novartis Investigative Site | Angers | France | قيد التجنيد |
| Novartis Investigative Site | Marseille | قيد التجنيد | |
| Novartis Investigative Site | Montpellier | قيد التجنيد |
Germany
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Novartis Investigative Site | Aachen | قيد التجنيد | |
| Novartis Investigative Site | Bochum | قيد التجنيد | |
| Novartis Investigative Site | Münster | قيد التجنيد | |
| Novartis Investigative Site | Tübingen | قيد التجنيد | |
| Novartis Investigative Site | Ulm | قيد التجنيد |
Hungary
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Novartis Investigative Site | Budapest | قيد التجنيد | |
| Novartis Investigative Site | Szeged | قيد التجنيد |
Israel
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Tel Aviv Sourasky Med Ctr Ichilov | Tel Aviv | قيد التجنيد |
Italy
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Novartis Investigative Site | Bologna | BO | قيد التجنيد |
| Novartis Investigative Site | Brescia | BS | قيد التجنيد |
| Novartis Investigative Site | Milan | MI | قيد التجنيد |
| Novartis Investigative Site | Milan | MI | قيد التجنيد |
Japan
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Novartis Investigative Site | Bunkyo Ku | Tokyo | قيد التجنيد |
| Novartis Investigative Site | Kashihara | Nara | قيد التجنيد |
| Novartis Investigative Site | Sagamihara | Kanagawa | قيد التجنيد |
Netherlands
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Novartis Investigative Site | Leiden | South Holland | قيد التجنيد |
| Novartis Investigative Site | Maastricht | Limburg | قيد التجنيد |
Poland
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Novartis Investigative Site | Krakow | POL | قيد التجنيد |
Portugal
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Novartis Investigative Site | Lisbon | قيد التجنيد | |
| Novartis Investigative Site | Porto | قيد التجنيد |
Romania
| المنشأة | المدينة | الولاية أو المنطقة | الحالة |
|---|---|---|---|
| Novartis Investigative Site | Bucharest | قيد التجنيد |
يُدرَج 67 موقعاً إضافياً في سجل السجل.
مستندات الدراسة
لا تُرتبط أي مستندات في سجل السجل هذا.
التغيّرات عبر الزمن
- 22 سبتمبر 2026
أُضيف موقع
35 sites added (117 total)
82117
- 31 أغسطس 2026
أُضيف موقع
22 sites added (82 total)
6082
- 11 أغسطس 2026
أُضيف موقع
9 sites added (60 total)
5160
- 29 يوليو 2026
أُضيف موقع
10 sites added (51 total)
4151